49 min
ASCO 2024 Summary Part 2 Lung Cancer Considered
-
- Science
In episode two summarizing important lung cancer data presented at ASCO 2024, Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu cover the phase III CROWN trial, ROS1 NSCLC with a novel ROS1 TKI, taletrectinib, the MARIPOSA trial, the PALOMA-3 trial, the WU-KONG1 data, the BEAMION-Lung1 trial, and CheckMate 77T.
Guest: Dr. Clarissa Mathias is the Director of NOB/Oncoclinicas in Brazil, a member of the ASCO International Quality Steering Group and Lung Cancer Committee, and a previous IASLC Board Member.
Guest: Dr. Delvys Rodriguez-Abreu is the Head of Medical Oncology at Hospital Universitario Insular de Gran Canaria and President of the Canarian Lung Cancer Foundation.
In episode two summarizing important lung cancer data presented at ASCO 2024, Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu cover the phase III CROWN trial, ROS1 NSCLC with a novel ROS1 TKI, taletrectinib, the MARIPOSA trial, the PALOMA-3 trial, the WU-KONG1 data, the BEAMION-Lung1 trial, and CheckMate 77T.
Guest: Dr. Clarissa Mathias is the Director of NOB/Oncoclinicas in Brazil, a member of the ASCO International Quality Steering Group and Lung Cancer Committee, and a previous IASLC Board Member.
Guest: Dr. Delvys Rodriguez-Abreu is the Head of Medical Oncology at Hospital Universitario Insular de Gran Canaria and President of the Canarian Lung Cancer Foundation.
49 min